Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 4 de 4
Filter
Add more filters










Database
Publication year range
1.
Schweiz Arch Tierheilkd ; 150(10): 499-505, 2008 Oct.
Article in German | MEDLINE | ID: mdl-18821509

ABSTRACT

Since 2003, the Research Institute of Organic Agriculture (FiBL) is realizing a herd health management programme ("pro-Q" project) focussing on udder health. The objectives of the project are: (1) to reduce antibiotic mastitis treatments, (2) to optimise udder health and (3) to improve longevity, measured as averaged number of herd lactations. The farms get expert advice in prevention and treatment on herd- and animal-level. After 2 years, treatment recordings of the 65 investigated farms showed that antibiotic mastitis therapies were reduced from 38 to 26 treatments per 100 cows and year (equals a reduction of 32%). Lactation numbers of the herds increased significantly by 0.2 lactations from 3.3 to 3.5 lactations per cow. Udder health remained constant over all farms during 2 years: theoretical bulk milk cell counts averaged constantly at around 180000 cells/ml. Improvement of udder health on farm level was significantly influenced by higher somatic cell count when the project started and enhanced by farmer's motivation and farm-veterinarians' commitment to the project.


Subject(s)
Anti-Bacterial Agents/therapeutic use , Dairying/methods , Mammary Glands, Animal/physiology , Mastitis, Bovine/drug therapy , Milk/standards , Animals , Cattle , Dairying/statistics & numerical data , Female , Mammary Glands, Animal/pathology , Mammary Glands, Animal/physiopathology , Milk/cytology , Veterinary Medicine/methods
3.
Br J Cancer ; 78(2): 233-9, 1998 Jul.
Article in English | MEDLINE | ID: mdl-9683299

ABSTRACT

Vascular endothelial growth factor (VEGF) expression and mutations of cancer-related genes increase with cancer progression. This correlation suggests the hypothesis that oncogenes and tumour suppressors regulate VEGF, and a significant correlation between p53 alteration and increased VEGF expression in human lung cancer was reported recently. To further examine this hypothesis, we analysed VEGF protein expression and mutations in p53 and K-ras in 27 non-small-cell lung cancers (NSCLC): 16 squamous cell, six adenocarcinomas, one large cell, two carcinoids and two undifferentiated tumours. VEGF was expressed in 50% of the squamous cell carcinomas (SCC) and carcinoids but none of the others. p53 mutations occurred in 14 tumours (52%), and K-ras mutations were found in two adenocarcinomas and one SCC; there was no correlation between the mutations and VEGF expression. As nitric oxide also regulates angiogenesis, we examined NOS expression in NSCLC. The Ca2+-dependent NOS activity, which indicates NOS1 and NOS3 expression, was significantly reduced in lung carcinomas compared with adjacent non-tumour tissue (P < 0.004). Although the Ca2+-independent NOS activity, which indicates NOS2 expression, was low or undetectable in non-tumour tissues and most carcinomas, significant activity occurred in three SCC. In summary, our data do not show a direct regulation of VEGF by p53 in NSCLC. Finally, we did not find the up-regulation of NOS isoforms during NSCLC progression that has been suggested for gynaecological and breast cancers.


Subject(s)
Endothelial Growth Factors/analysis , Genes, p53 , Lung Neoplasms/chemistry , Lymphokines/analysis , Nitric Oxide Synthase/analysis , Carcinoma, Small Cell/chemistry , Carcinoma, Small Cell/genetics , Carcinoma, Squamous Cell/chemistry , Carcinoma, Squamous Cell/genetics , Genes, p53/physiology , Genes, ras , Humans , Lung Neoplasms/genetics , Mutation , Nitric Oxide Synthase Type II , Vascular Endothelial Growth Factor A , Vascular Endothelial Growth Factors
4.
Cancer Res ; 58(2): 334-41, 1998 Jan 15.
Article in English | MEDLINE | ID: mdl-9443414

ABSTRACT

An increased expression of nitric oxide synthase (NOS) has been observed in human colon carcinoma cell lines as well as in human gynecological, breast, and central nervous system tumors. This observation suggests a pathobiological role of tumor-associated NO production. Hence, we investigated NOS expression in human colon cancer in respect to tumor staging, NOS-expressing cell type(s), nitrotyrosine formation, inflammation, and vascular endothelial growth factor expression. Ca2+-dependent NOS activity was found in normal colon and in tumors but was significantly decreased in adenomas (P < 0.001) and carcinomas (Dukes' stages A-D: P < 0.002). Ca2+-independent NOS activity, indicating inducible NOS (NOS2), is markedly expressed in approximately 60% of human colon adenomas (P < 0.001 versus normal tissues) and in 20-25% of colon carcinomas (P < 0.01 versus normal tissues). Only low levels were found in the surrounding normal tissue. NOS2 activity decreased with increasing tumor stage (Dukes' A-D) and was lowest in colon metastases to liver and lung. NOS2 was detected in tissue mononuclear cells (TMCs), endothelium, and tumor epithelium. There was a statistically significant correlation between NOS2 enzymatic activity and the level of NOS2 protein detected by immunohistochemistry (P < 0.01). Western blot analysis of tumor extracts with Ca2+-independent NOS activity showed up to three distinct NOS2 protein bands at Mr 125,000-Mr 138,000. The same protein bands were heavily tyrosine-phosphorylated in some tumor tissues. TMCs, but not the tumor epithelium, were immunopositive using a polyclonal anti-nitrotyrosine antibody. However, only a subset of the NOS2-expressing TMCs stained positively for 3-nitrotyrosine, which is a marker for peroxynitrite formation. Furthermore, vascular endothelial growth factor expression was detected in adenomas expressing NOS2. These data are consistent with the hypothesis that excessive NO production by NOS2 may contribute to the pathogenesis of colon cancer progression at the transition of colon adenoma to carcinoma in situ.


Subject(s)
Adenoma/enzymology , Colonic Neoplasms/enzymology , Neovascularization, Pathologic/enzymology , Nitric Oxide Synthase/metabolism , Adenoma/blood supply , Adenoma/pathology , Blotting, Western , Carcinoma/blood supply , Carcinoma/enzymology , Carcinoma/pathology , Colon/enzymology , Colonic Neoplasms/blood supply , Colonic Neoplasms/pathology , DNA Primers/chemistry , DNA, Neoplasm/analysis , Disease Progression , Endothelial Growth Factors/metabolism , Endothelium, Vascular/enzymology , Humans , Immunohistochemistry , Lymphokines/metabolism , Neoplasm Proteins/analysis , Nitric Oxide Synthase Type II , Phosphorylation , Polymerase Chain Reaction , Tyrosine/analogs & derivatives , Tyrosine/metabolism , Vascular Endothelial Growth Factor A , Vascular Endothelial Growth Factors
SELECTION OF CITATIONS
SEARCH DETAIL
...